Geisinger and Indivumed announce formal partnership
DANVILLE – Geisinger Health System has announced a partnership with Indivumed, a leading provider of services enabling individualized cancer therapy, that will afford Geisinger patients access to advanced cancer treatment and clinical trials, according to a press release issued jointly by the two organizations.
The partnership plans were announced in May 2013 and a formal agreement was reached last week.
The collaboration allows samples to be collected from consenting patients who are already undergoing a surgical tumor resection. A portion of the tissue, blood or urine remaining beyond what is required to make a clinical diagnosis will be banked at Geisinger through MyCode, a repository that holds more than 45,000 patient samples. Another portion will be banked by Indivumed, which will analyze the tissue to be used in the development and eventual application of targeted therapies for cancer patients.
“We are pleased to be working on this next generation of cancer treatment with Indivumed, a company recognized as a global leader in the field of biobanking and translational research,” said Glenn D. Steele Jr., president and chief executive officer at Geisinger Health System. “This partnership will give Geisinger patients access to the most advanced cancer therapeutics in the country, close to where they live and work.”
“Developing targeted pharmaceutical therapies for cancer patients is at the core of our collaboration with Geisinger,” said Hartmut Juhl, founder and chief executive officer of Indivumed. “Geisinger’s advanced electronic health record and clinical data repository coupled with our ability to comprehensively analyze patients’ individual cancers provides a unique opportunity to quickly translate new scientific discoveries into the practice of medicine.”
Indivumed will integrate its biobanking standard at Geisinger Health System to create a platform that offers opportunities for clinical research focused on tumor biology.
Indivumed follows highly standardized processes enabling it to limit time between removal of tissue from the body and preservation to less than 10 minutes, guaranteeing tissue samples of high biological integrity.
“The goal of this partnership is to translate clinical research into specific knowledge about a cancer that is clinically relevant and will enhance patient care,” Steele said. “We continually strive to look for innovation opportunities to provide our patients with the most advanced care modern science has to offer.”